Astrocyte reactivity to Fas activation is attenuated in TIMP-1 deficient mice, an in vitro study

BACKGROUND: Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a multifunctional secreted protein with pleiotropic actions, including the inhibition of matrix metalloproteinases (MMPs), cell death/survival and growth promoting activities. After inflammatory challenge, the levels of TIMP-1 are highly and selectively upregulated in astrocytes among glial cells, but little is know about its role in these neural cells. We investigated the influence of TIMP-1 null mutation in the reactivity of cultured astrocytes to pro-inflammatory stimuli with TNF-α and anti-Fas antibody. RESULTS: When compared to WT, mutant astrocytes displayed an overall increased constitutive gelatinase expression and were less responsive to Fas-mediated upregulation of MMP-9, of monocyte chemoattractant protein-1 (MCP-1) and of intercellular cell adhesion molecule-1 (ICAM-1), all markers of astrocyte inflammatory response. In contrast, TNF-α treatment induced all these factors similarly regardless of the astrocyte genotype. The incorporation of (3)H-thymidin, a marker of cell proliferation, increased in wild-type (WT) astrocytes after treatment with anti-Fas antibody or recombinant TIMP-1 but not in mutant astrocytes. Finally, lymphocyte chemotaxis was differentially regulated by TNF-α in WT and TIMP-1 deficient astrocytes. CONCLUSION: We provide evidence that the alteration of the MMP/TIMP balance in astrocytes influences their reactivity to pro-inflammatory stimuli and that Fas activation modulates the expression of members of the MMP/TIMP axis. We hypothesise that the Fas/FasL transduction pathway and the MMP/TIMP system interact in astrocytes to modulate their inflammatory response to environmental stimuli

L' Encéphalomyélite auto-immune expérimentale, modèle d'étude des mécanismes de recrutement des cellules immunes dans le système nerveux central (Influence de TWEAK et de TIMP-1 dans le recrutement des cellules immunitaires dans le SNC au cours de l'EAE)

AIX-MARSEILLE2-BU Méd/Odontol. (130552103) / SudocSudocFranceF

Schematic representation of the Transwell migration assay.

<p>Fluorescently labeled lymphocytes (10⁶ cells/ml) are added into the upper chamber, in the presence or absence of chemokines in the lower chamber. Counting of cells retrieved from the lower chamber enables to determine the percentage of lymphocytes that fully migated through the choroidal epithelial cells. Staining protocols of the cell covered filters following the migration study allow defining the localization of lymphocytes within the filter/epithelium system, and approaching the route of transmigration.</p

The cellular model of the blood-CSF barrier.

<p>(A) Schematic representation of a choroidal villus and of the experimental set up illustrating the two-chamber culture device. Left: the choroidal epithelium which forms the actual tight barrier controlling access into the CSF [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0150945#pone.0150945.ref018" target="_blank">18</a>] delimits a stroma, in which the fenestrated vessels lacking a typical blood-brain barrier phenotype, express P-selectin [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0150945#pone.0150945.ref004" target="_blank">4</a>]. Right: The epithelial cell monolayer grown on the lower side of the filter separates the upper chamber corresponding to the blood/stromal or basolateral space, from the bottom chamber representing the CSF or apical compartment (adapted from [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0150945#pone.0150945.ref018" target="_blank">18</a>,<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0150945#pone.0150945.ref041" target="_blank">41</a>]. (B and C) Immunofluorescent staining of occludin (B) and claudin 1/3 (C) showing a typical intercellular distribution of the tight junction proteins in the confluent inverted monolayers of choroidal epithelial cells. (D) Immunofluorescent staining of Na⁺K⁺ ATPase and ABCC1, showing the expected respective apical and basolateral membrane localization in the choroidal epithelial cells. The left image is a close up of a single cell to better appreciate the polarity of distribution of the 2 proteins. Nuclei appear in blue. Arrows show the lateral cellular membranes best seen in the z direction by confocal analysis, arrowheads show the basal labeling of ABCC1.</p

Confocal analysis of T cell transmigration route.

<p>Successive optical Z-sections through the filter + epithelial cell system are represented in an apical to basal order. (A) The most apical confocal plane is at the level of the tight junction protein claudin 2. The T cell, barely visible in this section, emerges on the following plane at a tricellular corner (white arrowhead). The leading edge is then visualized in section 3, followed by the cell body in more basal focal planes. A second, presumably transmigrating T cell similarly appears at another tricellular corner (Section 4, white arrow). (B) The T cell visible in the first confocal plane (white arrowhead) has migrated through the epithelial monolayer. It is located apically relative to the sections displaying the tight junction protein claudin 2 (visible from section 3), and associated with a tricellular corner (Section 5), through which it may have migrated. A second T cell (Section 7, white arrow) is visible in the second half of the plane series. It is mostly present in sections that are basal to the tight junction network.</p

Activated T cell migration across the choroidal epithelium.

<p>(A) Transepithelial chemotaxis of PHA-activated T cells in response to CCL2, CCL5 and CXCL10. **: statistically different from migration without chemokines p<0.01, two-tail Student's t test for unequal variance. The migration indices, measured after a 7-hour period, represent means ± SD, n = 3 or 4. (B) T cell chemotaxis does not alter the paracellular gate function of the blood-CSF barrier. Epithelial permeability coefficients for the paracellular marker sucrose are calculated and expressed in cm.min^-1 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0150945#pone.0150945.ref021" target="_blank">21</a>]. ns: not statistically different from control group (without T cells) p<0.05, one-way ANOVA followed by ‘a posteriori’ Dunnett’s test. Data represent means ± SD, n = 3.</p

Distribution of claudins and activated T cell localization following transmigration assay across the choroidal epithelium.

<p>T cell adhesion to and migration across the epithelium do not cause any alteration in the continuous peripheral distribution of epithelial tight junction proteins claudin 1/3 and 2. Stacks of optical Z-sections obtained by confocal microscopy across the whole filter + epithelial layer allowed visualizing all T cells associated with the system. Their relative position with respect to the tight junctions revealed by claudin1/3 (A, B, D, G) or claudin 2 (C, E, F) immunocytochemistry was determined in xz or yz views and used to discriminate transmigrated immune cells adhering to the apical membrane from those still located basolaterally or remaining in the upper chamber (example in B). Activated T cells contacting either the basolateral or the apical membrane domain of the epithelium are often located at tricellular corners (A, C, E, F) hinting at a paracellular route of T cell migration across the monolayer. Most T cells present a non-homogeneous fluorescence intensity or a typical comma-like shape with a uropod and a cellular protrusion that could be a leading edge (stars in A, D), which reflect their motility. In G, the T cell “a” extends a long cytoplasmic projection seemingly scanning the intercellular junction towards the tricellular corner.</p

Changes in Blood B Cell Phenotypes and Epstein‐Barr Virus Load in Chronically Human Immunodeficiency Virus–Infected Patients before and after Antiretroviral Therapy

International audienceBecause transitional-like B cells persist concomitantly with high EBV load after highly active antiretroviral therapy, we suggest that this population might be an alternative EBV reservoir in patients with chronic HIV infection who have strongly reduced numbers of memory B cells. The consequences of EBV infection of immature B cells are discussed with regard to B cell maturation and a higher prevalence of B cell lymphoma in HIV‐infected patients

TWEAK is expressed at the cell surface of monocytes during multiple sclerosis.

International audienceThe TNF superfamily ligand, TNF-like weak inducer of apoptosis (TWEAK), regulates cellular responses ranging from proliferation to cell death in a manner highly dependent on the cell type and the microenvironmental context. We have shown previously that treatment of experimental autoimmune encephalomyelitis mice after the priming phase with neutralizing anti-TWEAK antibodies results in a reduction in the severity of the disease and leukocyte infiltration. To further characterize TWEAK/fibroblast growth factor-inducible 14-kDa protein (Fn14) involvement during multiple sclerosis (MS), we evaluated in MS patients and controls: TWEAK and Fn14 expression on PBMC and soluble TWEAK concentration in serum and cerebrospinal fluid (CSF). Thirty-six consecutive patients were enrolled, including 11 patients with relapsing-remitting MS, 11 with a clinical isolated syndrome suggestive of MS (CISSMS), and 14 controls with non-MS diseases. Intracellular TWEAK could be observed in lymphocytes and/or monocytes in all groups of patients. None of the 36 patients displayed TWEAK expression at the cell surface of lymphocytes. In contrast, 12 out of the 36 patients were positive for membrane TWEAK expression on their monocytes. Among these patients, eight were from the CISSMS group. Fn14 was not detected in PBMC. The soluble form of TWEAK is detectable in serum and CSF of patients, and TWEAK concentrations were not statistically different between the disease groups. We demonstrated for the first time that TWEAK is expressed at the cell surface of monocytes during MS, especially in the CISSMS group. Our results support the proposal that TWEAK could be a target for antibody therapy in MS